Skip to content
Medical Health Aged Care, National News Current Affairs

Payroll Tax Imposition to Affect Dental Practices and Patients

Australian Dental Association 2 mins read

24.08.23 

Payroll Tax Imposition to Affect Dental Practices and Patients 

A new way of applying payroll tax to dental practice could result in inflated fees, impacting patients’ ability to afford vital treatment, the Australian Dental Association (ADA) warned today. 

Just as the Australian Medical Association has warned with doctors and its impact on patients, the move by state revenue offices to update an interpretation of an existing law would lead to financially devastating retrospective payroll tax penalties for dentists, as well as increased dental fees and even practice closures.  

It comes as the NSW Opposition this week moved an amendment in Parliament to support medical and dental clinics, by providing time for independent contractors to align with revenue offices’ new position. 

The ADA is urging the NSW and other state and territory governments to rethink new guidance which suggests medical and dental practice operators might need to make provisions for payroll taxes of between 5.45% and 6.85%, dating back five years. 

Independent contractor dentists working under a service facility agreement may be deemed employees for the purposes of payroll tax, leading to sudden and retrospective liabilities for practice operators, and uncertainties around their self-assessment.  

At a time when the Australian Senate is examining access to dental services in Australia, cost-of-living additions like this by state and territory governments will be unpopular with practitioners and their patients who’ll need to pay more to cover the extra costs.  

Dentists haven’t passed on fee increases recently. The ADA’s Dental Fees Survey shows that on average, fees charged by general dental practitioners increased by only about 2.14% between 2017 and 2022 – a period in which inflation increased by 14.5%. 

“Deemed payroll taxes on non-employee dentists would be a huge blow to those dentists, practice operators and the patients they serve,” said ADA CEO Damian Mitsch.  

“Some dentists are already struggling to keep their practices going as we recover from the business impacts of COVID-19 and costs rising with inflationary pressures. Unexpected tax liabilities would only make things worse and may precipitate dental practice closures.” 

He added: “We’re calling on MPs to support a payroll tax amnesty for all medical clinics including dental ones, proposed by the NSW Opposition.   

“Also, the new interpretations lack clarity, especially for practice operators who had, to their knowledge and according to professional advice, always been complying with payroll tax regulation.  

“There are dental clinics that are now contemplating closure or increasing their prices to cover what they may be forced to pay out in future and going back five years. 

“This benefits no-one, reduces the access to much needed dental care and further adds to costs faced by families. 

“To-date both the Queensland and South Australian Governments have implemented amnesties to support medical GPs - however none have yet contemplated the impact of the measures on other frontline health clinics like dental clinics.

“Governments should ensure dentists are included in any consultations and adjustments to their planned approach,” added Mr Mitsch, “because they are affected in the same way as GPs, and with comparable foreseeable effects on public health.”

To interview Damian Mitsch (pictured), call ADA Media Advisor Jenny Barlass 0484 869 086


Contact details:

Jenny Barlass 0484 869086

Media

More from this category

  • Medical Health Aged Care
  • 17/09/2024
  • 22:56
Ripple Therapeutics

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.Ripple's patented technology platform is based on…

  • Medical Health Aged Care
  • 17/09/2024
  • 15:11
Galderma

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and long-term efficacy of nemolizumab in prurigo…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/09/2024
  • 08:40
UNSW Sydney

New electricity-free soft robot could aid precise surgery

Biomedical engineers have developed a new soft robotic system that works without electricity or motors, allowing for more precise surgeries at lower cost. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.